{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-091693","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.487562+00:00","generated_at":"2026-05-18T12:41:36.996330+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025","bullets":["Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.","VISTA-inhibiting antibody renamed TBS-2025; TuHURA plans Phase 2 trial in NPM1 mutated AML in 2H 2025.","Acquisition unlocks fourth tranche of $12.5M PIPE financing announced June 3, 2025.","TuHURA believes TBS-2025 can overcome acquired resistance to cancer immunotherapy; exploring ADC synergies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-091693","json":"https://secwatch.observer/filing/0000950170-25-091693.json","markdown":"https://secwatch.observer/filing/0000950170-25-091693.md","text":"https://secwatch.observer/filing/0000950170-25-091693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/0000950170-25-091693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/hura-20250630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T12:41:36.996330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea65876c6809e477feb2a16a63a58142f5e92d50","claim":"TuHURA Biosciences, Inc./NV completed an acquisition involving Kineta, Inc. for 0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock (closed 2025-06-30).","evidence_excerpt":"share of Kineta common stock, par value $0.001 per share (each, a “Share”), issued and outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of TuHURA common stock, par value $0.001 per share (“TuHURA Common Stock”), for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock. Also pursuant to the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017025091693/0000950170-25-091693-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Kineta, Inc."},{"label":"Consideration","value":"0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock"},{"label":"Closing","value":"2025-06-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}